| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP and CFO | SVP and CFO
1 company
Martin Samuel Bates is a SVP and CFO at CLDX. Recent filings cover 1 purchase and 11 sales. Those positions are worth an estimated $342K at current prices.
Our model assigns Martin Samuel Bates a middling insider score of 67/100, based on 7 past trades. Over a 12-month horizon, 85.7% of those trades were profitable, with an average 12-month return of +20.1%.
Martin Samuel Bates's largest disclosed position is in CLDX as SVP and CFO, worth about $342K. The recent filings there lean toward selling, a net 84,160 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | CLDX Celldex Therapeutics, Inc. | SVP and CFO | Sale+OE | 17,172 | $35.42 | $608,314.67 | -37.9% | +20.4% | -38.7% | |
| May 30, 2024 | CLDX Celldex Therapeutics, Inc. | SVP and CFO | Sale+OE | 35,000 | $34.05 | $1,191,774.50 | -58.2% | +14.4% | -41.2% | |
| Aug 12, 2022 | CLDX Celldex Therapeutics, Inc. | SVP and CFO | Sale+OE | 20,000 | $36.52 | $730,485.09 | -45.1% | +1.3% | -19.0% | |
| Dec 23, 2021 | CLDX Celldex Therapeutics, Inc. | SVP and CFO | Sale+OE | 9,500 | $42.00 | $399,000.00 | -28.0% | -19.5% | +5.0% | |
| Nov 15, 2021 | CLDX Celldex Therapeutics, Inc. | SVP and CFO | Sale+OE | 9,500 | $43.57 | $413,883.36 | -26.1% | -26.4% | -14.7% | |
| Aug 10, 2021 | CLDX Celldex Therapeutics, Inc. | SVP and CFO | Sale+OE | 2,738 | $45.25 | $123,894.50 | -8.5% | -2.3% | -19.7% | |
| Jun 9, 2020 | CLDX Celldex Therapeutics, Inc. | SVP and CFO | Buy | 9,750 | $3.05 | $29,737.50 | +989.8% | - | - |